BPDCN

BPDCN patients at increased risk of second primary malignancies
June 01, 2020

Rare aggressive cutaneous lymphoma puts patients at risk of thyroid and non-lymphocytic leukemia second primary malignancies, researchers say.

Genetic features pave way for targeted BPDCN therapies
June 01, 2020

Dermatologists might be the first providers to encounter patients with blastic plasmacytoid dendritic cell neoplasm because more than 70% of these patients have cutaneous lesions. With one approved treatment and several in clinical trials, there are promising and much needed therapeutic options coming.

Investigational agents to treat hematologic malignancy in pipeline
May 04, 2020

Blastic plasmacytoid dendritic neoplasm (BPDCN) is a rare but aggressive hematologic malignancy that often manifests with asymptomatic skin lesions that often appear as bruise-like lesions, plaques or nodules. With one approved drug available, researchers are studying additional investigational agents.